Abstract Introduction MET exon 14 (METex14) skipping is a rare oncogenic driver in non–
small-cell lung cancer (NSCLC) for which targeted therapy with MET tyrosine kinase …

Purpose Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non–
small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact …

Purpose: We sought to investigate the clinical response to MET inhibition in patients
diagnosed with structural MET alterations and to characterize their functional relevance in …

Because MET exon 14 skipping mutations have been reported as biomarkers predicting
response to tyrosine kinase inhibitors, searching for MET mutations has become mandatory …

Met proto-oncogene exon 14 skipping (METex14) mutations are targetable driver genes in
approximately 3% of non-small-cell lung cancers (NSCLCs). Ensartinib, a type Ia MET …

Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter
of tyrosine kinase inhibitor (TKI) resistance in non–small cell lung cancer (NSCLC) …

Although several factors could be responsible for the negative results of the study, it is
possible that the potential benefit produced by the anti-MET agent was not detected …

Background: Savolitinib is a potent and selective MET tyrosine kinase inhibitor. It
demonstrated clinical efficacy and a manageable safety profile in Chinese NSCLC pts with …

Background MET exon 14 skipping mutations (METex14) occur in 3–4% of patients (pts)
with NSCLC. Accurate detection of the genomic variants that result in METex14 in MET …

Abstract Introduction MET exon 14 (METex14) skipping mutations occur in 3–4% of non-
small-cell lung cancer (NSCLC) cases. Currently, four oral MET tyrosine kinase inhibitors …